Molnupiravir Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Application (Influenza, Ebola, COVID-19, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region
Global Molnupiravir market may register impressive growth in the forecast period, 2023-2027, due to rising demands for effective pharmaceuticals for the rising cases of COVID-19. The high prevalence of the disease coupled with the viral variant complicates the conditions of the patients and thus leading to severe conditions of the infection and causing death for the population, driving the growth of the global Molnupiravir market in the upcoming five years. Furthermore, increasing research and development activities by various pharmaceutical & biotechnology players for the development of potential antiviral drugs is anticipated to foster market growth.
Molnupiravir is an orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV2, the causative agent of COVID-19. In simpler terms, the pharmaceutical product Molnupiravir is an orally administered drug that has higher potency as compared to other antiviral drugs against COVID-19. The drug has the chemical composition of mRNA that can act against the viral, and COVID infection-causing virus’ RNA. This RNA sequence has an effect against the new SARS-CoV2 too is thus used for controlling the effects of COVID-19.
Rising Instances of COVID-19 Drives Market Growth
Growing instances of COVID-19-positive cases are a major factor driving the growth of the global Molnupiravir market in the upcoming five years. Although through effective vaccinations and the use of precautionary steps, the rapid growth in the cases has been controlled. Although, growing variants of the virus and its evolving effect on the human body affect lives, and thus the demand for efficient pharmaceuticals such as Molnupiravir increases thereby supporting the growth of the global Molnupiravir market in the next five years.
As of 24th May 2022, there are already 528.37 million CVID-19 cases around the world, out of which 85.11 million cases belong to the United States itself. With the viral infection affecting such a large population in the country, the United States government had hastily authorized the administration of Molnupiravir to patients suffering from the mild symptoms of COVID-19. The orally administered capsules had certain concerns and side effects in their early phase-outs. Soon followed by the affordability of the drug as compared to other available treatment drugs, the industry for the drug expanded and with Clinical Phase III human trials already approved, the drug is expected to substantially grow in the forecast years.
Investments & Advancement Wheel In Further Market Growth
Rising investment in the pharmaceutical industry and growing expenses from the consumers toward effective drug development and overcoming the disease drives the growth of the global Molnupiravir market in the upcoming five years. Consumers are eager to adapt to more advanced, highly effective, and efficient drugs. If these drugs are affordable and are available in the local pharmaceutical markets, the distribution channel efficiency further fuels the growth of the global Molnupiravir market in the next five years.
In 2021, more than 3 million courses of Molnupiravir were supplied to the U.S. government within approximately 7 weeks of receiving emergency use authorization from the U.S. food and drug administration. The demands for drugs are high in the North American region looking at the growing instances of the cases in the country. Further evolutions in other pharmaceuticals and advancements in the innovative COVID-19 restricting drugs may create restraint on the growth of the market.
Market Segmentation
The global Molnupiravir market segmentation is based on application, distribution channel, regional distribution, and competitive landscape. Based on application, the market is fragmented into influenza, Ebola, COVID-19, and others. By distribution channel, the market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The market analysis also studies the regional segmentation, divided among the Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.
Company Profile
Merck Sharp & Dohme Corp., Everest Organics Limited, Optimus Drugs Pvt Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Mylan N.V., Emcure Pharmaceuticals Ltd., Sun Pharmaceutical Industries Limited, Hetero Drugs Ltd., Torrent Pharmaceuticals Ltd., are enlisted in a partial list of major market players of the global Molnupiravir market.
Report Scope:
In this report, global Molnupiravir market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in global Molnupiravir market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Molnupiravir is an orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV2, the causative agent of COVID-19. In simpler terms, the pharmaceutical product Molnupiravir is an orally administered drug that has higher potency as compared to other antiviral drugs against COVID-19. The drug has the chemical composition of mRNA that can act against the viral, and COVID infection-causing virus’ RNA. This RNA sequence has an effect against the new SARS-CoV2 too is thus used for controlling the effects of COVID-19.
Rising Instances of COVID-19 Drives Market Growth
Growing instances of COVID-19-positive cases are a major factor driving the growth of the global Molnupiravir market in the upcoming five years. Although through effective vaccinations and the use of precautionary steps, the rapid growth in the cases has been controlled. Although, growing variants of the virus and its evolving effect on the human body affect lives, and thus the demand for efficient pharmaceuticals such as Molnupiravir increases thereby supporting the growth of the global Molnupiravir market in the next five years.
As of 24th May 2022, there are already 528.37 million CVID-19 cases around the world, out of which 85.11 million cases belong to the United States itself. With the viral infection affecting such a large population in the country, the United States government had hastily authorized the administration of Molnupiravir to patients suffering from the mild symptoms of COVID-19. The orally administered capsules had certain concerns and side effects in their early phase-outs. Soon followed by the affordability of the drug as compared to other available treatment drugs, the industry for the drug expanded and with Clinical Phase III human trials already approved, the drug is expected to substantially grow in the forecast years.
Investments & Advancement Wheel In Further Market Growth
Rising investment in the pharmaceutical industry and growing expenses from the consumers toward effective drug development and overcoming the disease drives the growth of the global Molnupiravir market in the upcoming five years. Consumers are eager to adapt to more advanced, highly effective, and efficient drugs. If these drugs are affordable and are available in the local pharmaceutical markets, the distribution channel efficiency further fuels the growth of the global Molnupiravir market in the next five years.
In 2021, more than 3 million courses of Molnupiravir were supplied to the U.S. government within approximately 7 weeks of receiving emergency use authorization from the U.S. food and drug administration. The demands for drugs are high in the North American region looking at the growing instances of the cases in the country. Further evolutions in other pharmaceuticals and advancements in the innovative COVID-19 restricting drugs may create restraint on the growth of the market.
Market Segmentation
The global Molnupiravir market segmentation is based on application, distribution channel, regional distribution, and competitive landscape. Based on application, the market is fragmented into influenza, Ebola, COVID-19, and others. By distribution channel, the market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The market analysis also studies the regional segmentation, divided among the Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.
Company Profile
Merck Sharp & Dohme Corp., Everest Organics Limited, Optimus Drugs Pvt Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Mylan N.V., Emcure Pharmaceuticals Ltd., Sun Pharmaceutical Industries Limited, Hetero Drugs Ltd., Torrent Pharmaceuticals Ltd., are enlisted in a partial list of major market players of the global Molnupiravir market.
Report Scope:
In this report, global Molnupiravir market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Molnupiravir Market, By Type:
- Influenza
- Ebola
- COVID-19
- Others
- Molnupiravir Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Molnupiravir Market, By Region:
- North America
- United States
- Mexico
- Canada
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Vietnam
- Philippines
- Indonesia
- Malaysia
- Europe
- France
- Germany
- United Kingdom
- Spain
- Italy
- Denmark
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kenya
Company Profiles: Detailed analysis of the major companies present in global Molnupiravir market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
2. RESEARCH METHODOLOGY
3. IMPACT OF COVID-19 ON GLOBAL MOLNUPIRAVIR MARKET
4. EXECUTIVE SUMMARY
5. VOICE OF CUSTOMER
5.1. Factors Contributing to Demand of Molnupiravir
5.2. Choice of Source for Procuring Molnupiravir
5.3. Source of Information
5.4. Barriers to Adoption of Molnupiravir
5.5. Brand Awareness
6. PHARMACODYNAMIC OVERVIEW OF MOLNUPIRAVIR
6.1. Mechanism of Action
6.2. Absorption
6.3. Volume of Distribution
6.4. Protein Binding
6.5. Metabolism
6.6. Route of Elimination
6.7. Half Life
6.8. Clearance
7. CLINICAL TRIALS
7.1. Ongoing Clinical Trials
7.2. Completed Clinical Trials
7.3. Terminated Clinical Trials
7.4. Clinical Trial Analysis
8. PATENT ANALYSIS
8.1. Patent Granted (2017-2021)
8.2. Patent Applications Filed
9. GLOBAL MOLNUPIRAVIR MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value & Volume
9.2. Market Share & Forecast
9.2.1. By Application (Influenza, Ebola, COVID-19, Others)
9.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
9.2.3. By Company (2021)
9.2.4. By Region
9.3. Pricing Analysis
9.4. Product Market Map
10. NORTH AMERICA MOLNUPIRAVIR MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value & Volume
10.2. Market Share & Forecast
10.2.1. By Application
10.2.2. By Distribution Channel
10.2.3. By Country
10.3. Pricing Analysis
10.4. North America: Country Analysis
10.4.1. United States Molnupiravir Market Outlook
10.4.1.1. Market Size & Forecast
10.4.1.1.1. By Value & Volume
10.4.1.2. Market Share & Forecast
10.4.1.2.1. By Application
10.4.1.2.2. By Distribution Channel
10.4.2. Mexico Molnupiravir Market Outlook
10.4.2.1. Market Size & Forecast
10.4.2.1.1. By Value & Volume
10.4.2.2. Market Share & Forecast
10.4.2.2.1. By Application
10.4.2.2.2. By Distribution Channel
10.4.3. Canada Molnupiravir Market Outlook
10.4.3.1. Market Size & Forecast
10.4.3.1.1. By Value & Volume
10.4.3.2. Market Share & Forecast
10.4.3.2.1. By Application
10.4.3.2.2. By Distribution Channel
11. EUROPE MOLNUPIRAVIR MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value & Volume
11.2. Market Share & Forecast
11.2.1. By Application
11.2.2. By Distribution Channel
11.2.3. By Country
11.3. Pricing Analysis
11.4. Europe: Country Analysis
11.4.1. France Molnupiravir Market Outlook
11.4.1.1. Market Size & Forecast
11.4.1.1.1. By Value & Volume
11.4.1.2. Market Share & Forecast
11.4.1.2.1. By Application
11.4.1.2.2. By Distribution Channel
11.4.2. Germany Molnupiravir Market Outlook
11.4.2.1. Market Size & Forecast
11.4.2.1.1. By Value & Volume
11.4.2.2. Market Share & Forecast
11.4.2.2.1. By Application
11.4.2.2.2. By Distribution Channel
11.4.3. United Kingdom Molnupiravir Market Outlook
11.4.3.1. Market Size & Forecast
11.4.3.1.1. By Value & Volume
11.4.3.2. Market Share & Forecast
11.4.3.2.1. By Application
11.4.3.2.2. By Distribution Channel
11.4.4. Italy Molnupiravir Market Outlook
11.4.4.1. Market Size & Forecast
11.4.4.1.1. By Value & Volume
11.4.4.2. Market Share & Forecast
11.4.4.2.1. By Application
11.4.4.2.2. By Distribution Channel
11.4.5. Spain Molnupiravir Market Outlook
11.4.5.1. Market Size & Forecast
11.4.5.1.1. By Value & Volume
11.4.5.2. Market Share & Forecast
11.4.5.2.1. By Application
11.4.5.2.2. By Distribution Channel
11.4.6. Denmark Molnupiravir Market Outlook
11.4.6.1. Market Size & Forecast
11.4.6.1.1. By Value & Volume
11.4.6.2. Market Share & Forecast
11.4.6.2.1. By Application
11.4.6.2.2. By Distribution Channel
12. ASIA-PACIFIC MOLNUPIRAVIR MARKET OUTLOOK
12.1. Market Size & Forecast
12.1.1. By Value & Volume
12.2. Market Share & Forecast
12.2.1. By Application
12.2.2. By Distribution Channel
12.2.3. By Country
12.3. Pricing Analysis
12.4. Asia-Pacific: Country Analysis
12.4.1. China Molnupiravir Market Outlook
12.4.1.1. Market Size & Forecast
12.4.1.1.1. By Value & Volume
12.4.1.2. Market Share & Forecast
12.4.1.2.1. By Application
12.4.1.2.2. By Distribution Channel
12.4.2. India Molnupiravir Market Outlook
12.4.2.1. Market Size & Forecast
12.4.2.1.1. By Value & Volume
12.4.2.2. Market Share & Forecast
12.4.2.2.1. By Application
12.4.2.2.2. By Distribution Channel
12.4.3. South Korea Molnupiravir Market Outlook
12.4.3.1. Market Size & Forecast
12.4.3.1.1. By Value & Volume
12.4.3.2. Market Share & Forecast
12.4.3.2.1. By Application
12.4.3.2.2. By Distribution Channel
12.4.4. Japan Molnupiravir Market Outlook
12.4.4.1. Market Size & Forecast
12.4.4.1.1. By Value & Volume
12.4.4.2. Market Share & Forecast
12.4.4.2.1. By Application
12.4.4.2.2. By Distribution Channel
12.4.5. Australia Molnupiravir Market Outlook
12.4.5.1. Market Size & Forecast
12.4.5.1.1. By Value & Volume
12.4.5.2. Market Share & Forecast
12.4.5.2.1. By Application
12.4.5.2.2. By Distribution Channel
12.4.6. Vietnam Molnupiravir Market Outlook
12.4.6.1. Market Size & Forecast
12.4.6.1.1. By Value & Volume
12.4.6.2. Market Share & Forecast
12.4.6.2.1. By Application
12.4.6.2.2. By Distribution Channel
12.4.7. Philippines Molnupiravir Market Outlook
12.4.7.1. Market Size & Forecast
12.4.7.1.1. By Value & Volume
12.4.7.2. Market Share & Forecast
12.4.7.2.1. By Application
12.4.7.2.2. By Distribution Channel
12.4.8. Indonesia Molnupiravir Market Outlook
12.4.8.1. Market Size & Forecast
12.4.8.1.1. By Value & Volume
12.4.8.2. Market Share & Forecast
12.4.8.2.1. By Application
12.4.8.2.2. By Distribution Channel
12.4.9. Malaysia Molnupiravir Market Outlook
12.4.9.1. Market Size & Forecast
12.4.9.1.1. By Value & Volume
12.4.9.2. Market Share & Forecast
12.4.9.2.1. By Application
12.4.9.2.2. By Distribution Channel
13. SOUTH AMERICA MOLNUPIRAVIR MARKET OUTLOOK
13.1. Market Size & Forecast
13.1.1. By Value & Volume
13.2. Market Share & Forecast
13.2.1. By Application
13.2.2. By Distribution Channel
13.2.3. By Country
13.3. Pricing Analysis
13.4. South America: Country Analysis
13.4.1. Brazil Molnupiravir Market Outlook
13.4.1.1. Market Size & Forecast
13.4.1.1.1. By Value & Volume
13.4.1.2. Market Share & Forecast
13.4.1.2.1. By Application
13.4.1.2.2. By Distribution Channel
13.4.2. Argentina Molnupiravir Market Outlook
13.4.2.1. Market Size & Forecast
13.4.2.1.1. By Value & Volume
13.4.2.2. Market Share & Forecast
13.4.2.2.1. By Application
13.4.2.2.2. By Distribution Channel
13.4.3. Colombia Molnupiravir Market Outlook
13.4.3.1. Market Size & Forecast
13.4.3.1.1. By Value & Volume
13.4.3.2. Market Share & Forecast
13.4.3.2.1. By Application
13.4.3.2.2. By Distribution Channel
14. MIDDLE EAST AND AFRICA MOLNUPIRAVIR MARKET OUTLOOK
14.1. Market Size & Forecast
14.1.1. By Value & Volume
14.2. Market Share & Forecast
14.2.1. By Application
14.2.2. By Distribution Channel
14.2.3. By Country
14.3. Pricing Analysis
14.4. MEA: Country Analysis
14.4.1. South Africa Molnupiravir Market Outlook
14.4.1.1. Market Size & Forecast
14.4.1.1.1. By Value & Volume
14.4.1.2. Market Share & Forecast
14.4.1.2.1. By Application
14.4.1.2.2. By Distribution Channel
14.4.2. Saudi Arabia Molnupiravir Market Outlook
14.4.2.1. Market Size & Forecast
14.4.2.1.1. By Value & Volume
14.4.2.2. Market Share & Forecast
14.4.2.2.1. By Application
14.4.2.2.2. By Distribution Channel
14.4.3. UAE Molnupiravir Market Outlook
14.4.3.1. Market Size & Forecast
14.4.3.1.1. By Value & Volume
14.4.3.2. Market Share & Forecast
14.4.3.2.1. By Application
14.4.3.2.2. By Distribution Channel
14.4.4. Kenya Molnupiravir Market Outlook
14.4.4.1. Market Size & Forecast
14.4.4.1.1. By Value & Volume
14.4.4.2. Market Share & Forecast
14.4.4.2.1. By Application
14.4.4.2.2. By Distribution Channel
15. MARKET DYNAMICS
15.1. Drivers
15.2. Challenges
16. MARKET TRENDS & DEVELOPMENTS
17. COMPETITIVE LANDSCAPE
17.1. Company Profiles
17.1.1. Company Details
17.1.2. Financials (As reported)
17.1.3. Key Market Focus and Geographical Presence
17.1.4. Pricing of Target Products
17.1.5. Market positioning
17.2. Merck Sharp & Dohme Corp.
17.3. Everest Organics Limited
17.4. Optimus Drugs Pvt Ltd.
17.5. Dr. Reddy’s Laboratories Ltd
17.6. Cipla Limited
17.7. Mylan N.V.
17.8. Emcure Pharmaceuticals Ltd.
17.9. Sun Pharmaceutical Industries Limited
17.10. Hetero Drugs Ltd.
17.11. Torrent Pharmaceuticals Ltd.
18. STRATEGIC RECOMMENDATIONS
2. RESEARCH METHODOLOGY
3. IMPACT OF COVID-19 ON GLOBAL MOLNUPIRAVIR MARKET
4. EXECUTIVE SUMMARY
5. VOICE OF CUSTOMER
5.1. Factors Contributing to Demand of Molnupiravir
5.2. Choice of Source for Procuring Molnupiravir
5.3. Source of Information
5.4. Barriers to Adoption of Molnupiravir
5.5. Brand Awareness
6. PHARMACODYNAMIC OVERVIEW OF MOLNUPIRAVIR
6.1. Mechanism of Action
6.2. Absorption
6.3. Volume of Distribution
6.4. Protein Binding
6.5. Metabolism
6.6. Route of Elimination
6.7. Half Life
6.8. Clearance
7. CLINICAL TRIALS
7.1. Ongoing Clinical Trials
7.2. Completed Clinical Trials
7.3. Terminated Clinical Trials
7.4. Clinical Trial Analysis
8. PATENT ANALYSIS
8.1. Patent Granted (2017-2021)
8.2. Patent Applications Filed
9. GLOBAL MOLNUPIRAVIR MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value & Volume
9.2. Market Share & Forecast
9.2.1. By Application (Influenza, Ebola, COVID-19, Others)
9.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
9.2.3. By Company (2021)
9.2.4. By Region
9.3. Pricing Analysis
9.4. Product Market Map
10. NORTH AMERICA MOLNUPIRAVIR MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value & Volume
10.2. Market Share & Forecast
10.2.1. By Application
10.2.2. By Distribution Channel
10.2.3. By Country
10.3. Pricing Analysis
10.4. North America: Country Analysis
10.4.1. United States Molnupiravir Market Outlook
10.4.1.1. Market Size & Forecast
10.4.1.1.1. By Value & Volume
10.4.1.2. Market Share & Forecast
10.4.1.2.1. By Application
10.4.1.2.2. By Distribution Channel
10.4.2. Mexico Molnupiravir Market Outlook
10.4.2.1. Market Size & Forecast
10.4.2.1.1. By Value & Volume
10.4.2.2. Market Share & Forecast
10.4.2.2.1. By Application
10.4.2.2.2. By Distribution Channel
10.4.3. Canada Molnupiravir Market Outlook
10.4.3.1. Market Size & Forecast
10.4.3.1.1. By Value & Volume
10.4.3.2. Market Share & Forecast
10.4.3.2.1. By Application
10.4.3.2.2. By Distribution Channel
11. EUROPE MOLNUPIRAVIR MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value & Volume
11.2. Market Share & Forecast
11.2.1. By Application
11.2.2. By Distribution Channel
11.2.3. By Country
11.3. Pricing Analysis
11.4. Europe: Country Analysis
11.4.1. France Molnupiravir Market Outlook
11.4.1.1. Market Size & Forecast
11.4.1.1.1. By Value & Volume
11.4.1.2. Market Share & Forecast
11.4.1.2.1. By Application
11.4.1.2.2. By Distribution Channel
11.4.2. Germany Molnupiravir Market Outlook
11.4.2.1. Market Size & Forecast
11.4.2.1.1. By Value & Volume
11.4.2.2. Market Share & Forecast
11.4.2.2.1. By Application
11.4.2.2.2. By Distribution Channel
11.4.3. United Kingdom Molnupiravir Market Outlook
11.4.3.1. Market Size & Forecast
11.4.3.1.1. By Value & Volume
11.4.3.2. Market Share & Forecast
11.4.3.2.1. By Application
11.4.3.2.2. By Distribution Channel
11.4.4. Italy Molnupiravir Market Outlook
11.4.4.1. Market Size & Forecast
11.4.4.1.1. By Value & Volume
11.4.4.2. Market Share & Forecast
11.4.4.2.1. By Application
11.4.4.2.2. By Distribution Channel
11.4.5. Spain Molnupiravir Market Outlook
11.4.5.1. Market Size & Forecast
11.4.5.1.1. By Value & Volume
11.4.5.2. Market Share & Forecast
11.4.5.2.1. By Application
11.4.5.2.2. By Distribution Channel
11.4.6. Denmark Molnupiravir Market Outlook
11.4.6.1. Market Size & Forecast
11.4.6.1.1. By Value & Volume
11.4.6.2. Market Share & Forecast
11.4.6.2.1. By Application
11.4.6.2.2. By Distribution Channel
12. ASIA-PACIFIC MOLNUPIRAVIR MARKET OUTLOOK
12.1. Market Size & Forecast
12.1.1. By Value & Volume
12.2. Market Share & Forecast
12.2.1. By Application
12.2.2. By Distribution Channel
12.2.3. By Country
12.3. Pricing Analysis
12.4. Asia-Pacific: Country Analysis
12.4.1. China Molnupiravir Market Outlook
12.4.1.1. Market Size & Forecast
12.4.1.1.1. By Value & Volume
12.4.1.2. Market Share & Forecast
12.4.1.2.1. By Application
12.4.1.2.2. By Distribution Channel
12.4.2. India Molnupiravir Market Outlook
12.4.2.1. Market Size & Forecast
12.4.2.1.1. By Value & Volume
12.4.2.2. Market Share & Forecast
12.4.2.2.1. By Application
12.4.2.2.2. By Distribution Channel
12.4.3. South Korea Molnupiravir Market Outlook
12.4.3.1. Market Size & Forecast
12.4.3.1.1. By Value & Volume
12.4.3.2. Market Share & Forecast
12.4.3.2.1. By Application
12.4.3.2.2. By Distribution Channel
12.4.4. Japan Molnupiravir Market Outlook
12.4.4.1. Market Size & Forecast
12.4.4.1.1. By Value & Volume
12.4.4.2. Market Share & Forecast
12.4.4.2.1. By Application
12.4.4.2.2. By Distribution Channel
12.4.5. Australia Molnupiravir Market Outlook
12.4.5.1. Market Size & Forecast
12.4.5.1.1. By Value & Volume
12.4.5.2. Market Share & Forecast
12.4.5.2.1. By Application
12.4.5.2.2. By Distribution Channel
12.4.6. Vietnam Molnupiravir Market Outlook
12.4.6.1. Market Size & Forecast
12.4.6.1.1. By Value & Volume
12.4.6.2. Market Share & Forecast
12.4.6.2.1. By Application
12.4.6.2.2. By Distribution Channel
12.4.7. Philippines Molnupiravir Market Outlook
12.4.7.1. Market Size & Forecast
12.4.7.1.1. By Value & Volume
12.4.7.2. Market Share & Forecast
12.4.7.2.1. By Application
12.4.7.2.2. By Distribution Channel
12.4.8. Indonesia Molnupiravir Market Outlook
12.4.8.1. Market Size & Forecast
12.4.8.1.1. By Value & Volume
12.4.8.2. Market Share & Forecast
12.4.8.2.1. By Application
12.4.8.2.2. By Distribution Channel
12.4.9. Malaysia Molnupiravir Market Outlook
12.4.9.1. Market Size & Forecast
12.4.9.1.1. By Value & Volume
12.4.9.2. Market Share & Forecast
12.4.9.2.1. By Application
12.4.9.2.2. By Distribution Channel
13. SOUTH AMERICA MOLNUPIRAVIR MARKET OUTLOOK
13.1. Market Size & Forecast
13.1.1. By Value & Volume
13.2. Market Share & Forecast
13.2.1. By Application
13.2.2. By Distribution Channel
13.2.3. By Country
13.3. Pricing Analysis
13.4. South America: Country Analysis
13.4.1. Brazil Molnupiravir Market Outlook
13.4.1.1. Market Size & Forecast
13.4.1.1.1. By Value & Volume
13.4.1.2. Market Share & Forecast
13.4.1.2.1. By Application
13.4.1.2.2. By Distribution Channel
13.4.2. Argentina Molnupiravir Market Outlook
13.4.2.1. Market Size & Forecast
13.4.2.1.1. By Value & Volume
13.4.2.2. Market Share & Forecast
13.4.2.2.1. By Application
13.4.2.2.2. By Distribution Channel
13.4.3. Colombia Molnupiravir Market Outlook
13.4.3.1. Market Size & Forecast
13.4.3.1.1. By Value & Volume
13.4.3.2. Market Share & Forecast
13.4.3.2.1. By Application
13.4.3.2.2. By Distribution Channel
14. MIDDLE EAST AND AFRICA MOLNUPIRAVIR MARKET OUTLOOK
14.1. Market Size & Forecast
14.1.1. By Value & Volume
14.2. Market Share & Forecast
14.2.1. By Application
14.2.2. By Distribution Channel
14.2.3. By Country
14.3. Pricing Analysis
14.4. MEA: Country Analysis
14.4.1. South Africa Molnupiravir Market Outlook
14.4.1.1. Market Size & Forecast
14.4.1.1.1. By Value & Volume
14.4.1.2. Market Share & Forecast
14.4.1.2.1. By Application
14.4.1.2.2. By Distribution Channel
14.4.2. Saudi Arabia Molnupiravir Market Outlook
14.4.2.1. Market Size & Forecast
14.4.2.1.1. By Value & Volume
14.4.2.2. Market Share & Forecast
14.4.2.2.1. By Application
14.4.2.2.2. By Distribution Channel
14.4.3. UAE Molnupiravir Market Outlook
14.4.3.1. Market Size & Forecast
14.4.3.1.1. By Value & Volume
14.4.3.2. Market Share & Forecast
14.4.3.2.1. By Application
14.4.3.2.2. By Distribution Channel
14.4.4. Kenya Molnupiravir Market Outlook
14.4.4.1. Market Size & Forecast
14.4.4.1.1. By Value & Volume
14.4.4.2. Market Share & Forecast
14.4.4.2.1. By Application
14.4.4.2.2. By Distribution Channel
15. MARKET DYNAMICS
15.1. Drivers
15.2. Challenges
16. MARKET TRENDS & DEVELOPMENTS
17. COMPETITIVE LANDSCAPE
17.1. Company Profiles
17.1.1. Company Details
17.1.2. Financials (As reported)
17.1.3. Key Market Focus and Geographical Presence
17.1.4. Pricing of Target Products
17.1.5. Market positioning
17.2. Merck Sharp & Dohme Corp.
17.3. Everest Organics Limited
17.4. Optimus Drugs Pvt Ltd.
17.5. Dr. Reddy’s Laboratories Ltd
17.6. Cipla Limited
17.7. Mylan N.V.
17.8. Emcure Pharmaceuticals Ltd.
17.9. Sun Pharmaceutical Industries Limited
17.10. Hetero Drugs Ltd.
17.11. Torrent Pharmaceuticals Ltd.
18. STRATEGIC RECOMMENDATIONS
